Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of CXA-201 plus metronidazole versus meropenem in complicated intraabdominal infection
2011-002120-41Phase 3Completed
- Sponsor
- Cubist Pharmaceuticals, Inc.
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ceftolozane + tazobactam in Intra-abdominal infection (IAI) (2 arms), sponsored by Cubist Pharmaceuticals, Inc. Primary endpoint: Clinical cure rate at test-of-cure (TOC) visit in primary MITT population. Started Nov 2011; status: completed.
02
Drugs
ceftolozane + tazobactam
03
Conditions
Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on 2011-002120-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002120-41.